Articles from Jupiter Endovascular, Inc.

Jupiter Endovascular, Inc. today announced that the SPIRARE II pivotal trial evaluating the use of the company’s Vertex™ Pulmonary Embolectomy System in patients with acute, intermediate-risk pulmonary embolism (PE) met both of its primary endpoints, demonstrating meaningful heart recovery and clinical safety. Late-breaking data from the trial were presented today by Catalin Toma, MD, Director of Interventional Cardiology at the UPMC Heart and Vascular Institute and the trial’s Global Co-Principal Investigator, at EuroPCR 2026 in Paris, France.

Jupiter Endovascular, Inc., a medical technology company developing a new class of endovascular interventions using its proprietary Transforming Fixation (TFX) technology, today announced completion of patient enrollment in the SPIRARE II pivotal clinical trial evaluating the Vertex™ Pulmonary Embolectomy System in patients with acute, intermediate-risk pulmonary embolism (PE). The final subject was enrolled by Vikas Aggarwal, MD, Interventional Cardiologist at Henry Ford Hospital and the site’s Principal Investigator.

Jupiter Endovascular, Inc., a medical technology startup developing a new class of endovascular procedures using its proprietary Transforming Fixation (TFX) technology, today announced it has closed an oversubscribed Series B financing that surpassed its $40 million target. The round was led by Sonder Capital, with participation from Senvest Management, LB Investment, and a new strategic corporate investor. The proceeds will be used to complete Jupiter’s ongoing SPIRARE II pivotal clinical trial, prepare for commercialization, and develop new clinical applications for its TFX platform technology.

Jupiter Endovascular, Inc., a medical technology startup transforming endovascular medicine with a new class of interventions, announced today that experienced medtech finance and operations executive Fred Ong has joined the company as Chief Financial Officer.

Jupiter Endovascular, Inc., a medical technology startup developing a new class of endovascular procedures using Endoportal Control™, announced today that the first U.S. patient has been treated in the SPIRARE II U.S. pivotal study of the Vertex Pulmonary Embolectomy System featuring the company’s Endoportal Control™ platform technology. The Vertex system is designed to treat Acute Pulmonary Embolism (PE) in an innovative endovascular procedure offering an unprecedented level of control and precision.

Jupiter Endovascular, Inc., a medical technology startup developing a new class of endovascular procedures using Endoportal Control™, announced today that the first two patients have been treated in SPIRARE I (NCT06571760), a multicenter study of the Vertex Pulmonary Embolectomy System using the company’s Endoportal Control™ platform technology. The Vertex system is designed to treat Acute Pulmonary Embolism (PE) in an innovative endovascular procedure offering an unprecedented level of control and precision.

Jupiter Endovascular, Inc., a medical technology startup developing a new class of endovascular procedures using Endoportal Control™ to bring the precision and control of direct surgical access to catheter-based interventions, announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption application for the SPIRARE II U.S. pivotal study (NCT06576427).

Jupiter Endovascular, Inc., a medical technology startup developing a new class of endovascular procedures using Endoportal ControlTM to bring the precision and control of direct surgical access to catheter-based interventions, announced today that it has exited stealth mode with a $21 million new round of financing. Sonder Capital was a key participant in the round that included participation from multiple strategic investors. The funding will be used to support the company’s upcoming pivotal trial for Pulmonary Embolism and development of additional clinical applications of the Endoportal ControlTM technology.